A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 815 participants.
Also called NCT07218029
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 815 participants
- Sponsor
- Registry
-
NCT07218029 -
2025-521970-33-00 -
U1111-1321-4943
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Argentina, Australia, Belgium, Brazil, Canada, Colombia, Croatia, Czechia, Denmark, France, Germany, Greece, Israel, Italy, Mexico, Netherlands, New Zealand, Poland, Portugal, Serbia, South Korea, Spain, Sweden, Switzerland, Taiwan, United Kingdom
- Registry status
- Active, not recruiting
Technical summary
Registry record NCT07218029. Allocation not applicable; no masking; primary purpose treatment. Start 2021-05-12 (actual); primary completion 2028-12-07 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)
- Acronym
- SOTERIA
- Condition
- Pulmonary Arterial Hypertension
- Intervention (Biological)
- Sotatercept
- Lead sponsor
- Merck Sharp & Dohme LLC
Record details
- Record id
cardio:ct-nct07218029- Content hash
b8808948b48a224a012a9d836bedeaa4ca018e59d0b215f9045af9ecc8f55f41